Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluorouracil, quantity: 5000 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

Israel - English - Ministry of Health

abic marketing ltd, israel - fluorouracil - solution for injection - fluorouracil 50 mg/ml - fluorouracil - fluorouracil - palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas, in selected patients considered incurable by surgery or other means.as leucovorin-fluorouracil chemotherapy combination for cancer treatment.

United States - English - NLM (National Library of Medicine)

solco healthcare us llc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 20 mg in 1 ml - fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. in the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. safety and efficacy in other indications have not been established. the diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. with isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. the success rate with fluorouracil solution is approximately 93%, based on 113 lesions in 54 patients. twenty-five lesions treated with the solution produced 1 failure. fluorouracil may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies in pregnant women with either the topical or the parenteral forms of fluorouracil. one birth defect (cleft

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 50 mg in 1 g - fluorouracil cream is recommended for the topical treatment of multiple actinic or solar keratoses. in the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. safety and efficacy in other indications have not been established. the diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. with isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. the success rate with fluorouracil cream is approximately 93%, based on 113 lesions in 54 patients. eighty-eight lesions treated with the cream produced 7 failures. fluorouracil cream may cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies in pregnant women with either the topical or the parenteral forms of fluorouracil. one birth defec

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fluorouracil, quantity: 1000 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon, rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervcial particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - fluorouracil, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered impractical.